Skip to content
type1.science

NewcelX NCEL-101 / IsletRx

NewcelX

What it is

A pre-IND stem-cell-derived islet replacement program for insulin-dependent T1D, which NewcelX plans to pair with Eledon's anti-CD40L antibody tegoprubart in a calcineurin-inhibitor-free immunosuppression regimen. That is a lighter drug burden, not freedom from drugs — anti-CD40L is itself chronic systemic immunosuppression. An FDA pre-IND meeting was completed in July 2026; no IND has been filed, no trial is open, and there is no human data.

Editorial review: .

Most recent recorded citation date: 2026-07-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Years awayPreclinicalstem-cellisletpre-indcell-therapytegoprubartOfficial site ↗

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Preclinical evidence. Benefit in people has not been established.
Benefit or performance
Insulin independence: No human data yet; the program is pre-IND and has not entered a first-in-human trial.[2]
Important harms and treatment burden
Immunosuppression-free: Scored at the same level as zimislecel — lifelong systemic immunosuppression — because that is what is planned. Pairing NCEL-101 with anti-CD40L tegoprubart in a calcineurin-inhibitor-free protocol is a lighter immune burden, not a drug-free one: anti-CD40L is itself chronic systemic immunosuppression, and in the one islet trial where this regimen is actually running it is given on top of ATG/basiliximab, mycophenolate and etanercept. It previously scored 25, above zimislecel; we removed the premium because it rewarded an intention. This regimen exists on paper — the program is pre-IND, with no human data of any kind.[3]
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Durability: Durability is a stated goal, especially with tegoprubart immune modulation, but remains preclinical.[3]

Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. This speculative assessment includes intended performance or preclinical findings; it does not establish benefit in people.

Default calculation: 8 × 30 + 12 × 20 + 20 × 20 + 40 × 10 + 15 × 10 + 12 × 10 = 1550; divide by total weight 100. Unrounded weighted result: 15.5.

Insulin independence8

No human data yet; the program is pre-IND and has not entered a first-in-human trial.[2]

Durability12

Durability is a stated goal, especially with tegoprubart immune modulation, but remains preclinical.[3]

Immunosuppression-free20

Scored at the same level as zimislecel — lifelong systemic immunosuppression — because that is what is planned. Pairing NCEL-101 with anti-CD40L tegoprubart in a calcineurin-inhibitor-free protocol is a lighter immune burden, not a drug-free one: anti-CD40L is itself chronic systemic immunosuppression, and in the one islet trial where this regimen is actually running it is given on top of ATG/basiliximab, mycophenolate and etanercept. It previously scored 25, above zimislecel; we removed the premium because it rewarded an intention. This regimen exists on paper — the program is pre-IND, with no human data of any kind.[3]

Low invasiveness40

As an islet replacement therapy it will require transplantation or infusion; final route is not yet publicly established.[1]

Eligibility breadth15

Potentially scalable if it reaches clinic, but eligibility is undefined before the IND and first protocol.[2]

Maturity12

Pre-IND package submitted May 2026; a company-described successful FDA Type B pre-IND meeting followed in July 2026, with the company reporting favourable feedback on manufacturing and preclinical data — but this is still pre-IND, with no first-in-human trial open and no announced IND date.[4]

The full picture

NewcelX is not yet a clinical competitor to Vertex or Sana, but it is now visible enough to track. The company-reported May 2026 pre-IND package submission and Eledon collaboration put NCEL-101 on the horizon for first-in-human testing. The scientific bet is familiar: manufacture insulin-producing islet cells, then pair them with immune modulation strong enough to protect the graft without the worst transplant-drug burden.

Where it stands, July 2026

NewcelX announced on 1 July 2026 that it had completed a Type B pre-IND meeting with the FDA.4 According to the company, the agency gave favourable feedback on its manufacturing (CMC) processes and its preclinical package, and there was alignment on the proposed development strategy — clearing NewcelX to move on to IND-enabling work. That is a real step forward from a package merely being submitted, but it is worth being precise about what it is not: no Investigational New Drug application has been filed, no trial-start date has been announced, and no human has yet received NCEL-101.

Note also that the FDA does not publish pre-IND meeting outcomes, so everything we know about how that meeting went comes from NewcelX's own press release. The fact that the meeting happened is solid; the adjective "successful" is the company's.

NewcelX describes NCEL-101 as an enriched stem-cell-derived islet product — the company says roughly 60% of the beta cells co-express insulin and NKX6.1, and that 99.98% of the product is of endocrine lineage.4 These are manufacturer figures from a press release, not independently verified or peer-reviewed data. The plan remains to pair the cells with Eledon's anti-CD40L antibody tegoprubart in a calcineurin-inhibitor-free immunosuppressive regimen — a lighter immune burden than the standard transplant drug cocktail, but still immunosuppression, not freedom from it.

Coming soon

ETA · FDA Type B pre-IND meeting completed (July 2026); IND-enabling work under way, with no IND filing or trial-start date announced

Sources

  1. [1]
  2. [2]
  3. [3]
  4. [4]
    NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes · Manufacturer · 2026-07-01 — Company press release. The FDA does not publish pre-IND meeting outcomes, so the characterisation of the feedback and the cell-purity figures are manufacturer claims.

    NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes — NewcelX press release, 1 July 2026.